Effects of dialyzable transfer factor in patients with breast cancer.
Five patients with advanced breast cancer were treated with pooled dialyzable transfer factor from healthy adult donors. The period of treatment ranged from 21 to 310 days, the total dose from 20 to 257 ml. Transfer factor did not elicit inflammatory or hypersensitivity reactions or detectable formation of antibody to itself, nor any hematological or biochemical abnormalities or other side effects. Three patients became responsive (by skin test) to tuberculin and/or streptococcal antigens. Marked partial regression of the breast cancer, lasting 6 months, was observed in one patient.
D000328:Adult; D000368:Aged; D000907:Antibodies, Bacterial; D000912:Antibodies, Neoplasm; D000917:Antibody Formation; D000942:Antigens, Bacterial; D001943:Breast Neoplasms / Q000276:immunology / Q000628:therapy*; D002277:Carcinoma / Q000276:immunology / Q000628:therapy*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000276:immunology / Q000628:therapy*; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007111:Immunity, Cellular; D007112:Immunity, Maternally-Acquired; D007116:Immunization, Passive; D007167:Immunotherapy; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009362:Neoplasm Metastasis; D013291:Streptococcus / Q000276:immunology; D014374:Tuberculin Test
D000907:Antibodies, Bacterial; D000912:Antibodies, Neoplasm; D000942:Antigens, Bacterial